Last reviewed · How we verify
Group LL
At a glance
| Generic name | Group LL |
|---|---|
| Also known as | Chirocaine 0.25% |
| Sponsor | Ankara University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects Of Low-Load Blood Flow Restriction Training Of The Upper Extremity In Patients With Chronic Obstructive Pulmonary Disease (NA)
- High-Load, Low-Load, and Passive Blood Flow Restriction in Competitive Sprinters (NA)
- Effect of Cross-Education in Blood Flow Restriction Resistance Training on Lower Limbs in Older Women (NA)
- an Observational Study Evaluting the Effectiveness and Safety of DKutting LL Noval Scoring Balloon Angioplasty for Vessel Preparation Facilitated by IVUS on the Lower Limb Ischemia Patients With Calcified Lesions
- A Novel Remineralizing Self-Etch Primer for Orthodontic Bracket Bonding (NA)
- Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) (PHASE2, PHASE3)
- Gait and Paraspinal sEMG in Degenerative Spinal Diseases
- Effect of Electrically Insulated Gloves on ROSC Time, End-tidal CO₂ Response, Survival and Morbidity in Uninterrupted CPR (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Group LL CI brief — competitive landscape report
- Group LL updates RSS · CI watch RSS
- Ankara University portfolio CI